Stimulating pharmaceutical research and development for neglected diseases

被引:24
|
作者
Mrazek, MF [1 ]
Mossialos, E [1 ]
机构
[1] Univ London London Sch Econ & Polit Sci, LSE Hlth & Social Care, London WC2A 2AE, England
关键词
neglected diseases; pharmaceutical research and development; public-private partnerships; PUBLIC-PRIVATE PARTNERSHIPS; INFECTIOUS-DISEASES; COUNTRIES; DRUGS; TUBERCULOSIS; MALARIA; WORLD;
D O I
10.1016/S0168-8510(02)00138-0
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
New vaccines and drug treatments are needed for tackling the neglected diseases (NDs) of poor countries. These diseases are associated with high levels of mortality and/or morbidity, but lack appropriate vaccines and drug treatments because of bacterial resistance, toxicity, long-treatment protocols, problems with administration or because none are available. Current initiatives directed at research and development (R&D) of NDs are being led predominantly by the governmental, inter-governmental and private not-for-profit sectors implemented by way of public-private partnerships. Push and pull mechanisms targeted at the pharmaceutical industry have also been proposed as another way to stimulate RD of NDs; however, these should be viewed with some caution. Stimulating R&D for NDs is important as part of a wider long-term public health strategy and must be addressed simultaneously with resolving more immediate problems of access to medicines and health system sustainability in less developed countries. (C) 2002 Published by Elsevier Science Ireland Ltd.
引用
收藏
页码:75 / 88
页数:14
相关论文
共 50 条
  • [41] Vaccines for neglected, emerging and re-emerging diseases
    Madhav, Archana
    Mehrotra, Tanshi
    Sinha, Pallavi
    Mutreja, Ankur
    SEMINARS IN IMMUNOLOGY, 2020, 50
  • [42] Intersectoral approaches to neglected diseases
    Ault, Steven K.
    REDUCING THE IMPACT OF POVERTY ON HEALTH AND HUMAN DEVELOPMENT: SCIENTIFIC APPROACHES, 2008, 1136 : 64 - 69
  • [43] Co-authorship Network Analysis: A Powerful Tool for Strategic Planning of Research, Development and Capacity Building Programs on Neglected Diseases
    Morel, Carlos Medicis
    Serruya, Suzanne Jacob
    Penna, Gerson Oliveira
    Guimaraes, Reinaldo
    PLOS NEGLECTED TROPICAL DISEASES, 2009, 3 (08):
  • [44] Neglected tropical rheumatic diseases
    Rasmi Ranjan Sahoo
    Anupam Wakhlu
    Vikas Agarwal
    Clinical Rheumatology, 2022, 41 : 1293 - 1304
  • [45] Bridging the innovation gap for neglected tropical diseases in Mexico: capacity building for the development of a new generation of antipoverty vaccines
    Elena Bottazzi, Maria
    Dumonteil, Eric
    Valenzuela, Jesus G.
    Betancourt-Cravioto, Miguel
    Tapia-Conyer, Roberto
    Hotez, Peter J.
    BOLETIN MEDICO DEL HOSPITAL INFANTIL DE MEXICO, 2011, 68 (02):
  • [46] One step forward, one step sideways? Expanding research capacity for neglected diseases
    Lexchin, Joel
    BMC INTERNATIONAL HEALTH AND HUMAN RIGHTS, 2010, 10
  • [47] Incentives for Starting Small Companies Focused on Rare and Neglected Diseases
    Ekins, Sean
    Wood, Jill
    PHARMACEUTICAL RESEARCH, 2016, 33 (04) : 809 - 815
  • [48] Global partnerships are critical to advance the control of Neglected Zoonotic Diseases: The case of the Global Alliance for Rabies Control
    Nel, Louis H.
    Taylor, Louise H.
    Balaram, Deepashree
    Doyle, Kim A. S.
    ACTA TROPICA, 2017, 165 : 274 - 279
  • [49] Basel: A Hotspot for Drug Discovery and Development Against Poverty-related Diseases
    Meier, Lukas
    CHIMIA, 2023, 77 (09) : 613 - 615
  • [50] From bench to clinic: bridging the translational gap in neglected disease drug development
    Ruminski, Peter G.
    FUTURE MEDICINAL CHEMISTRY, 2011, 3 (10) : 1253 - 1257